QCG
AKRO

Quadrant Capital Group’s Akero Therapeutics AKRO Stock Holding History

Quadrant Capital Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-559
Closed -$26.5K – 2711
2025
Q3 		$26.5K Buy
+559
New +$27.1K ﹤0.01% 1863
2025
Q2 		– Sell
-573
Closed -$23.2K – 1366
2025
Q1 		$23.2K Hold
573
– – ﹤0.01% 1995
2024
Q4 		$15.9K Hold
573
– – ﹤0.01% 1981
2024
Q3 		$16.4K Hold
573
– – ﹤0.01% 1975
2024
Q2 		$13.4K Sell
573
-146
-20% -$3.12K ﹤0.01% 2016
2024
Q1 		$18.2K Buy
719
+93
+15% +$2.23K ﹤0.01% 1889
2023
Q4 		$14.6K Buy
626
+15
+2% +$296 ﹤0.01% 1927
2023
Q3 		$30.9K Hold
611
– – ﹤0.01% 1500
2023
Q2 		$28.5K Hold
611
– – ﹤0.01% 1538
2023
Q1 		$23.4K Sell
611
-85
-12% -$3.79K ﹤0.01% 1620
2022
Q4 		$38.1K Buy
696
+28
+4% +$1.2K ﹤0.01% 1335
2022
Q3 		$23K Buy
668
+111
+20% +$1.7K ﹤0.01% 1461
2022
Q2 		$5K Buy
+557
New +$5.81K ﹤0.01% 1934

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quadrant Capital Group's AKRO Position: Q4 2025 in Review

Quadrant Capital Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 559 shares — an estimated $26.5K sold.

Quadrant Capital Group first reported a position in AKRO in Q2 2022 and held it in 13 quarters. The position peaked at $38.1K in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Quadrant Capital Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 559 Akero Therapeutics shares in Q4 2025, an estimated $26.5K.
  • Quadrant Capital Group first reported a position in Akero Therapeutics in Q2 2022 and held it in 13 quarters.
  • Quadrant Capital Group's Akero Therapeutics position peaked at $38.1K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.